Alteogen said on the 26th that it confirmed the effect of improving drug delivery efficiency of its recombinant hyaluronidase "ALT-B4" in a preclinical study of large-volume subcutaneous (SC) injection conducted with U.S. medical device corporations Becton Dickinson (BD).
The company unveiled the findings at the PDA Miniverse 2026 conference held in Dublin on the 21st–22nd of this month (local time). PDA Miniverse is an international conference in which global corporations in injectables, drug-delivery systems, and combination products participate, and it addresses key agendas such as large-volume drug delivery and technologies to improve patient convenience.
Alteogen Chief Executive Jeon Tae-yeon personally attended the presentation to introduce the results of the joint study with BD. The study was conducted to evaluate drug delivery rate and subcutaneous tissue response when applying Alteogen's ALT-B4 to BD's 10 mL wearable injector (a body-attached syringe), "BD Libertas™."
According to BD's presentation materials, in a preclinical trial using a pig model, subcutaneous administration of a 10 mL large-volume drug mixed with ALT-B4 improved abdomen-based infusion time and injection rate compared with a formulation without ALT-B4. In addition, ultrasound and computed tomography (CT) analyses showed that applying ALT-B4 accelerated drug dispersion within subcutaneous tissue and that swelling at the injection site tended to resolve more quickly.
Jeon Tae-yeon of Alteogen said, "Through these BD preclinical results, we were able to reconfirm the competitiveness of ALT-B4," and added, "As development of high-dose biologics such as monoclonal and bispecific antibodies expands, we expect ALT-B4 to establish itself as a core drug-delivery solution."